Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
Rory J McCrimmonPhilip HomeAlice ChengFrancesco GiorginoVivian A FonsecaElisabeth SouhamiAgustina AlvarezPascaline PicardJulio RosenstockPublished in: Diabetes, obesity & metabolism (2022)
These results show that the lower HbA1c levels and weight benefit seen with iGlarLixi versus premixed BIAsp 30 in people with type 2 diabetes advancing their basal insulin therapy in the SoliMix trial are also accompanied by a lower risk of hypoglycaemia at any time of day and across a broad range of HbA1c levels.